Daily Endocrinology Research Analysis
Analyzed 68 papers and selected 3 impactful papers.
Summary
Three high-impact endocrinology studies span mechanistic aging biology, cardiometabolic outcomes, and cell-therapy engineering. A prespecified SELECT trial analysis shows semaglutide reduces cardiovascular events in people with obesity at high liver fibrosis risk; a Science Advances study reveals IGF-1 pathway longevity benefits require mitochondrial genome integrity; and a Nature Communications study demonstrates that early F-actin depolymerization enhances human stem cell-derived islet differentiation and function.
Research Themes
- Mitochondria-dependent modulation of endocrine aging pathways
- Incretin-based cardiometabolic therapy in obesity with liver fibrosis risk (MASLD)
- Cytoskeletal engineering to improve beta-cell replacement therapy
Selected Articles
1. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
In a prespecified secondary analysis of the SELECT RCT, semaglutide reduced MACE in obese adults without diabetes who were at high risk of liver fibrosis by FIB-4 criteria, and it produced greater improvements in fatty liver index than placebo over 104 weeks. Benefits were consistent across FIB-4 thresholds, with the strongest (but not statistically significant) reduction in the highest FIB-4 stratum.
Impact: This study extends SELECT’s cardiovascular findings to patients at risk for substantial liver fibrosis, linking GLP-1RA therapy to both hepatic and cardiovascular benefits in obesity without diabetes.
Clinical Implications: For patients with obesity and suspected advanced liver fibrosis risk (e.g., elevated FIB-4), semaglutide may confer cardiovascular protection and improve hepatic steatosis metrics even without diabetes, supporting integrated cardiometabolic-hepatology management and prioritization of GLP-1RA therapy in this subgroup.
Key Findings
- Semaglutide reduced MACE by 26% in patients with FIB-4 ≥1.3 and by 21% using age-specific FIB-4 thresholds.
- A nonsignificant 34% MACE reduction was observed in those with FIB-4 >2.67.
- Semaglutide produced a 28% greater decrease in fatty liver index versus placebo over 104 weeks.
Methodological Strengths
- Prespecified subgroup analysis within a large, event-driven randomized controlled trial
- Robust cardiovascular endpoint (MACE) adjudication and consistent findings across FIB-4 risk thresholds
Limitations
- Secondary analysis; FIB-4 is a noninvasive surrogate and not biopsy-proven fibrosis
- SELECT excluded patients with diabetes; generalizability to diabetes remains to be determined
Future Directions: Validate benefits across imaging- or biopsy-confirmed fibrosis stages; test whether combined cardiometabolic and hepatologic endpoints can guide therapy selection and timing in MASLD with high fibrosis risk.
In the SELECT trial, once-weekly subcutaneous semaglutide reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes. We examined semaglutide in SELECT patients at high risk for substantial liver fibrosis in a prespecified secondary analysis. Liver biochemical tests and steatosis risk according to fatty liver index were assessed over 104 weeks. Subgroup analyses of the primary MACE (a composite endpoint including cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) outcome used baseline Fibrosis-4 scores ≥ 1.3, age-specific (≥1.3 (<65 years) or ≥2.0 (≥65 years)) and any age with Fibrosis-4 > 2.67. MACE was reduced by 26% (hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.63-0.88; P = 0.0004), 21% (HR 0.79; 95% CI 0.63-0.98; P = 0.035) and 34% (HR 0.66; 95% CI 0.39-1.10; P = 0.11), respectively. Semaglutide led to a 28% greater decrease in fatty liver index versus placebo (HR 0.72; 95% CI 0.71-0.73; P < 0.0001). In conclusion, semaglutide reduced MACE versus placebo in patients at risk for substantial liver fibrosis, as seen in the overall SELECT population. ClinicalTrials.gov registration no. NCT03574597.
2. The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome.
Reduced IGF-1 signaling did not extend lifespan in mitochondrial mutator mice and key longevity pathways were blunted, indicating that mitochondrial genome stability is a prerequisite for IGF-1–mediated pro-longevity effects. This reveals a hierarchy among aging hallmarks and highlights preserving mitochondrial DNA integrity as a potential target to enable endocrine longevity pathways.
Impact: Identifies mitochondrial genome integrity as a gatekeeper for endocrine longevity signaling, reframing how IGF-1 suppression interfaces with aging biology and guiding combination strategies.
Clinical Implications: Although preclinical, the findings suggest that interventions aiming to lower IGF-1 signaling or mimic its effects may require concomitant strategies that maintain mitochondrial genome integrity to realize benefits, informing biomarker strategies and drug combinations.
Key Findings
- Reduced IGF-1 signaling failed to extend lifespan in mitochondrial mutator mice.
- Longevity pathways normally activated by IGF-1 suppression were blocked or blunted in mutator mice.
- Pro-longevity effects of IGF-1 suppression critically depend on mitochondrial genome integrity, revealing a hierarchy of aging pathways.
Methodological Strengths
- Use of a mitochondrial mutator mouse model to causally interrogate mitochondrial genome stability
- System-level assessment of longevity pathways under IGF-1 suppression across genotypes
Limitations
- Preclinical mouse model; translational relevance to humans requires validation
- Specific molecular intermediates linking mtDNA instability to pathway blunting remain to be fully defined
Future Directions: Define the molecular checkpoints that couple mitochondrial DNA instability to suppression of endocrine longevity pathways; test combination interventions that stabilize mitochondrial genomes alongside IGF-1 pathway modulation.
Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian life span and protects against a range of age-related diseases. Unexpectedly, we found that reduced IGF-1 signaling fails to extend the life span of mitochondrial mutator mice. Most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the prolongevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome, revealing an unexpected hierarchy in the pathways that control mammalian aging. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
3. Depolymerizing F-actin accelerates the exit from pluripotency to enhance stem cell-derived islet differentiation.
A transient 24-hour F-actin depolymerization at the start of definitive endoderm formation accelerates loss of pluripotency, rewires key signaling pathways, and improves pancreatic specification. The approach yields islets with higher β-cell content and function, reduces off-target enterochromaffin cells, and rescues poorly performing hPSC lines.
Impact: Introduces a simple, time-bound cytoskeletal perturbation that reproducibly improves hPSC-to-islet differentiation and in vivo function, addressing a key bottleneck for β-cell replacement therapies.
Clinical Implications: While preclinical, this strategy could standardize and upscale production of higher-quality β-cell grafts for diabetes cell therapy, potentially improving engraftment, glycemic control, and reducing off-target cell types.
Key Findings
- Latrunculin A–mediated F-actin depolymerization during the first 24 hours of endoderm induction accelerates exit from pluripotency and rewires Activin/Nodal, BMP, c-Jun, and WNT signaling.
- Enhanced pancreatic progenitor identity with reduced expression of non-pancreatic endodermal markers.
- Resulting islets show higher β-cell proportion, improved maturation and insulin secretion, reverse hyperglycemia in vivo, and have fewer enterochromaffin cells; the method rescues poorly differentiating hPSC lines.
Methodological Strengths
- Precise temporal cytoskeletal perturbation with mechanistic mapping of multiple signaling pathways
- Functional validation including in vivo reversal of hyperglycemia and reduction of off-target lineages
Limitations
- Preclinical in vitro/in vivo studies; safety, scalability, and GMP translation require further work
- Potential variability across hPSC lines and need to optimize dosing and timing for clinical manufacturing
Future Directions: Translate to GMP-compatible protocols, evaluate long-term graft safety/efficacy, and integrate with encapsulation or immune-evasion strategies for clinical β-cell replacement.
In this study, we demonstrate that cytoskeletal state at the onset of directed differentiation impacts the exit of human pluripotent stem cells (hPSCs) from pluripotency and downstream lineage specification. In particular, depolymerizing F-actin with latrunculin A (latA) during the first 24 h of definitive endoderm formation facilitates efficient loss of pluripotency and alters Activin/Nodal, BMP, c-Jun, and WNT signaling dynamics. These signaling changes influence downstream patterning of the gut tube, leading to improved pancreatic progenitor identity and decreased expression of markers associated with other endodermal lineages. Continued differentiation generates islets containing a higher percentage of β cells that exhibit improved maturation, insulin secretion, and ability to reverse hyperglycemia. Furthermore, this latA treatment reduces enterochromaffin cells in the final cell population and corrects differentiations from hPSC lines that otherwise fail to consistently produce pancreatic islets, highlighting the importance of cytoskeletal signaling at the onset of directed differentiation.